



Press release

Hørsholm
27 February 2014

ALK participates in the Credit Suisse 2014 London Healthcare Conference

Page 1/1

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will participate in the Credit Suisse One-on-One Healthcare Conference in London on 4 March 2014.

The Company will be represented by Flemming Pedersen, CFO and EVP and Per Plotnikof, Director IR and Strategic Planning.

On 4 March, Flemming Pedersen will be participating in the Credit Suisse Conference Panel Discussion “**Investing for future growth – go alone or partner?**” taking place at 10.00 AM.

ALK-Abelló A/S

For further information please contact:

Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations:

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609 466 0466, mobile +1 732 319 2833, e-mail:

janetdally@maidstonelifesci.com

Press:

Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise sublingual allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.